Ethan Russo forwards his paper,

Grand Unified Theory (GUT): The Endocannabinoid System, Cannabis and the Microbiome

just published in Frontiers of Integrative Neuroscience

Russo notes:

“This article addresses five critical areas of clinical neurology practice wherein conventional medicine has fallen short:

1) epilepsy, 2) brain tumors, 3) Parkinson disease, 4) Alzheimer disease, 5) traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE), and how cannabis-based treatment and nutritional approaches with prebiotics and probiotics may

provide more effective treatment.”

The paper, which will be the basis of Russo’s talk at the CannMed conference in LA October 23, begins with this overview:

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of

neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes.

 

While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain.

 

This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to

neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD),

their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD)

and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE).

 

Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB1 and CB2(tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPARγ; THCA), 5-HT1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics.

 

The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional

and even preventative treatment.

https://www.thescientistschannel.com/ethan-russo

YouTube with Ehtan Russo:

https://www.google.com/search?q=ethan+russo+images+free&tbm=isch&ved=2ahUKEwimgt2m_t70AhXSADQIHeL4BTgQ2-cCegQIABAA&oq=ethan+russo+images+free&gs_lcp=CgNpbWcQAzoGCAAQBxAeULQcWJ4qYJMtaABwAHgAgAFoiAGhB5IBBDExLjGYAQCgAQGqAQtnd3Mtd2l6LWltZ8ABAQ&sclient=img&ei=PUy2YebvJdKB0PEP4vGXwAM&bih=880&biw=1920&rlz=1C1ZKTG_enUS804US804#imgrc=m2OmZsqY_yMJvM&imgdii=XB1wh9UZjF503M

Live interview with Martin Lee and Dr Russo

https://youtu.be/C-UwA2O6gA4

ethan russo.jpeg